NCT01021618View on ClinicalTrials.gov

Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging

NACompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Coronary Artery DiseaseMyocardial Ischemia
Interventions
DRUG

Regadenoson

Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging

OTHER

Symptom-limited exercise

Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging

Trial Locations (1)

06102

Hartford Hospital, Hartford

Sponsors

Collaborators (1)

Astellas Pharma Inc
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

Hartford Hospital

OTHER